Shire Competitors and Similar CompaniesClear all
Shire's competitors and similar companies include Pfizer, Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Biogen, Gilead Sciences, Amgen and Sanofi Genzyme.
 Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Alexion Pharmaceuticals Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases. |  Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. |  Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Sanofi Genzyme Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. | ||
Founding Date | Founding Date 1986 | Founding Date 1849 | Founding Date 1992 | Founding Date 1988 | Founding Date 1989 | Founding Date 1978 | Founding Date 1987 | Founding Date 1980 | Founding Date 1981 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||||||
Locations | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | Locations Boston, US HQ Frenchs Forest, AU Wien, AT Elsene, BE São Paulo, BR Vaughan, CA Shanghai, CN see more | Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Cambridge, US HQ Macquarie Park, AU Malaga, AU Virginia, AU São Paulo, BR Mississauga, CA Toronto, CA see more | ||
Employees | Employees 7,80441% increase | Employees 81,0008% decrease | Employees 10,6006% increase | Employees 15,1068% increase | Employees 5,40013% increase | Employees 7,605 | Employees 18,0006% increase | Employees 25,200 | Employees 9,9041% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 163.9 b | Valuation ($) 40.3 b | Valuation ($) 102.2 b | Valuation ($) 121.4 b | Valuation ($) 26.7 b | Valuation ($) 110.5 b | Valuation ($) 170.4 b | Valuation ($) N/A |
Financial | |||||||||
Revenue (est.) | Revenue (est.) £43m (FY, 2018) | Revenue (est.) $62.6b (FY, 2025) | Revenue (est.) $6.1b (FY, 2020) | Revenue (est.) $14.3b (FY, 2025) | Revenue (est.) $12b (FY, 2025) | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) $29.4b (FY, 2025) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) €10.4b (FY, 2019) |
Cost of goods | Cost of goods N/A | Cost of goods $16.1b (FY, 2025) | Cost of goods $553.5m (FY, 2020) | Cost of goods N/A | Cost of goods $1.7b (FY, 2025) | Cost of goods $2.4b (FY, 2025) | Cost of goods $6.2b (FY, 2025) | Cost of goods $12b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $46.5b (FY, 2025) | Gross profit $5.5b (FY, 2020) | Gross profit N/A | Gross profit $10.4b (FY, 2025) | Gross profit $7.5b (FY, 2025) | Gross profit $23.2b (FY, 2025) | Gross profit $24.7b (FY, 2025) | Gross profit N/A |
Net income | Net income £3.4m (FY, 2018) | Net income $7.8b (FY, 2025) | Net income $603.4m (FY, 2020) | Net income $4.5b (FY, 2025) | Net income N/A | Net income $1.3b (FY, 2025) | Net income $8.5b (FY, 2025) | Net income $7.7b (FY, 2025) | Net income N/A |
Operating ⚠ | |||||||||
Clinical Trials | Clinical Trials N/A | Clinical Trials N/A | Clinical Trials N/A | Clinical Trials N/A | Clinical Trials 3 (FY, 2022) | Clinical Trials N/A | Clinical Trials 104 (FY, 2019) | Clinical Trials N/A | Clinical Trials N/A |
Countries | Countries 100 (FY, 2017) | Countries 200 (FY, 2024) | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries 35 (FY, 2021) | Countries 100 (FY, 2020) | Countries 100 (Nov, 2020) |
Manufacturing Sites | Manufacturing Sites 14 (FY, 2017) | Manufacturing Sites 37 (FY, 2024) | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A |
Patents (EU) | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) 17 (FY, 2020) | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) 21 (FY, 2020) | Patents (EU) N/A |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) 605 (Nov, 2020) |
Phase I Trials Products | Phase I Trials Products 7 (FY, 2017) | Phase I Trials Products 51 (FY, 2024) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 4 (FY, 2024) | Phase I Trials Products N/A | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 10 (FY, 2017) | Phase II Trials Products 27 (FY, 2024) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2024) | Phase II Trials Products N/A | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 15 (FY, 2017) | Phase III Trials Products 32 (FY, 2024) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2024) | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A |
Products | Products N/A | Products N/A | Products 5 (Q1, 2021) | Products 11 (FY, 2022) | Products 6 (FY, 2022) | Products N/A | Products 21 (FY, 2021) | Products N/A | Products 25 (Nov, 2020) |
Funding | |||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 53.9m | Total funding raised $ 2.4m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Pfizer
HQ
New York, US
Employees
81,000↓ 8% decrease
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View companyAlexion Pharmaceuticals
HQ
Boston, US
Employees
10,600↑ 6% increase
Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases.
View companyRegeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
15,106↑ 8% increase
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
View companyVertex Pharmaceuticals
HQ
Boston, US
Employees
5,400↑ 13% increase
Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.
View company